Background: CD-19 Chimeric Antigen Receptor – T (CAR-T) cell therapy is FDA approved for the treatment of primary refractory or recurrent Diffuse Large B-Cell Lymphoma (DLBCL) after two or more lines of systemic therapies have failed. The two commercially available products are Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel). In clinical trials, 54% of 111 patients […]

Case Presentation: 39-year-old male with history of previously treated TB meningitis 15 years ago, chronic hydrocephalus who received endoscopic third ventriculostomy few months ago, presented again with headaches and was found to have hydrocephalus. Patient received Ventriculoperitoneal shunt placement and CSF was obtained after the procedure. CSF studies showed (216-WBCs lymphocytic predominant fluid 81 %), […]